Current Status of Semaglutide Injection andDevelopment Prospects in China

Abstract

Obesity is a global issue that closely affects public health, and China’s obesity rate is among the highest in the world. Recently, Semaglutide injection was approved for marketing in China as the first weekly formulation for long-term weight control. This review consolidates and analyzes various types of research related to Semaglutide regarding weight loss, to comprehensively describe the different aspects of the drug. As a glucagon-like peptide 1 receptor agonists (GLP-1RA), Semaglutide works by mimicking the action of innate hormone to enhance the cell signaling activity and corresponding outcome. It has been approved to effectively reduce weight and improve weight-related factors in overweight or obese patients with a guaranteed safety profile. Comparing to traditional methods of losing weight, this medication is time and effort-saving, which makes it highly competitive in this field. Although there are still unsolved issues and challenges faced by the drug, such as high price and acceptance among doctors and patients, it is highly likely to become a new and anticipated method of weight management in China